Prefilled Syringes or Peptide Pills? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prefilled Syringes or Peptide Pills?
The impact of new delivery technologies in designing peptide therapies.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 46-49

References

1. R. Lax, PharManufacturing website, "The Future of Peptide Development in the Pharmaceutical Industry," http://www.polypeptide.com/, accessed Apr. 4, 2013.

2. J. Reichert, Peptide Therapeutics Foundation website, "2010 Development Trends for Peptide Therapeutics," http://www.peptidetherapeutics.org/, accessed Apr. 4, 2013.

3. P. Vlieghe et al., Drug Discov. Today 15 (1-2) 40-56 (2010).

4. C.A. Lipinski et al., Adv. Drug Deliv. Rev. 46 (1-3) 3-26 (2001).

5. A. Ruggiero et al., Proc. Natl. Acad. Sci. USA 107 (27): 12369-12374 (2010).

6. J.L. Cleland et al., Curr. Opin. Biotechnol. 12 (2) 212-219 (2001).

7. Q. Ye et al., J Control. Rel. 64 (1-3) 155-166 (2000).

8. F. Tiberg and F. Johhnson, On Drug Delivery website, "Lipid-Liquid Crystals for Parenteral Sustained-Release Applications," http://www.ondrugdelivery.com/, accessed Apr. 4, 2013.

9. C. Valery et al., Proc. Natl. Acad. Sci. USA 100 (18) 10258-10262 (2003).

10. J. Heller, Adv. Drug Deliv. Rev. 10 (1-3) 163-204 (1993).

11. A. Lalatsa, "Peptide and Protein Therapeutics: Impact of New Delivery Technologies and Clinical Development" in Fundamentals of Pharmaceutical Nanosciences, I.F. Uchegbu, A.G. Schatzlein, W.P. Cheng and A. Lalatsa, Eds. (Springer, New York, 2013).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here